article · Journal of the Egyptian Womenʼs Dermatologic Society
Background Chemotherapy-induced alopecia is a distressing adverse effect of cancer therapy. Autologous hematopoietic stem cell transplantation (AHSCT) is widely used for hematological malignancies, yet limited data exist on longitudinal trichoscopic changes post-AHSCT. Objective To assess the severity, progression, and trichoscopic characteristics of hair changes following AHSCT and to evaluate correlations with chemotherapy regimen and clinical factors. Patients and methods A 6-month prospective observational study was conducted on 81 patients post-AHSCT. Scalp hair loss was quantified using the Severity of Alopecia Tool score. Trichoscopy was performed monthly using a handheld dermoscope (DermLite DL5). Patients were followed up monthly for 6 months. Results Black dots decreased significantly from 39.5 to 16.0% ( P =0.001). Terminal hairs increased from 75.3 to 98.8% ( P =0.001), and vellus hairs increased from 86.4 to 98.8% ( P =0.002). Scalp hair loss improved progressively, with 92.6% of patients showing less than 25% loss at month 6 compared with 63% at baseline ( P <0.001). Younger age was significantly associated with faster improvement ( P =0.04). Conclusion AHSCT‑related alopecia demonstrates a predictable pattern of clinical and trichoscopic improvement. Younger age may predict faster recovery. These findings aid in patient counseling and monitoring post-AHSCT.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4103/jewd.jewd_141_25
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.